A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Inclusion Criteria: * Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver * Male and female subjects 55-85 years of age inclusive * Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's * Mini Mental State Exam (MMSE-2) score of 4-15 * Patients must be able to perform at least one item on the Severe Impairment Battery Scale * Neuroimaging (computerized tomography (CT) or Magnetic Resonance Imaging (MRI)) within the last 24 months consistent with a diagnosis of probable Alzheimer's disease (AD) * Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week * Adequate vision and motor function to comply with testing * If taking drugs approved for treatment of Alzheimer's disease (e.g. cholinesterase inhibitors, memantine), must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse event or a clinically significant change in the patient's status. Exclusion Criteria: * Dementia due to any condition other than AD, including vascular dementia (Rosen-modified Hachinski lschemic score ≥ 5) * Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarct…